TAS266 

TAS266 is a tetrameric nanobody agonist targeting DR5. TAS266 selectively induces cancer cell death. TAS266 triggers sustained tumor regression in xenograft models and also elicits immunogenic responses including antibody binding. TAS266 exhibits superior anti-tumor efficacy compared with traditional DR5-targeting strategies. TAS266 can be used in research related to pancreatic cancer and advanced solid tumors^[1][2].

(VHH-VHH-hFc)-dimer

Human

TAS266 is up to 1000-fold more potent than cross-linked DR5 antibody or TRAIL at inducing cell death in cancer cell lines via DR5 activation, with faster downstream caspase activation kinetics^[1].
TAS266 potently induces death in human tumor cell lines, with potency ≥1000-fold greater than cross-linked DR5 antibody LBY135 or TRAIL^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

TAS266 (200 mg/kg; twice weekly) shows no target organ toxicity including hepatotoxicity in cynomolgus monkeys after administration, with its biological activity remaining intact^[2].
TAS266 (single dose; weekly) induces tumor regression in a variety of tumor xenograft models, and its antitumor activity with weekly administration is superior to that of DR5 agonist antibodies in pancreatic cancer and colon cancer xenograft models^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

8795  [NCBI]

O14763

TNFRSF10B/TRAILR2/CD262

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Huet H, et al. TAS266, a novel tetrameric nanobody agonist targeting death receptor 5 (DR5), elicits superior antitumor efficacy than conventional DR5-targeted approaches[J]. Cancer Research, 2012, 72(8_Supplement): 3853-3853.

  [2]. Papadopoulos KP, et al. Unexpected hepatotoxicity in a phase I study of TAS266, a novel tetravalent agonistic Nanobody® targeting the DR5 receptor. Cancer Chemother Pharmacol. 2015;75(5):887-895.  [Content Brief]